{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=5",
    "query": {
      "condition": "Uveal Melanoma",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 200,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uveal+Melanoma&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T23:46:03.653Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01200342",
      "title": "Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Genasense",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-12",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-02-11",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01200342"
    },
    {
      "nct_id": "NCT07136181",
      "title": "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Uveal Melanoma",
        "Uveal Melanoma, Metastatic",
        "Uveal Melanoma, Recurrent",
        "Eye Cancer, Intraocular Melanoma",
        "Eye Cancer"
      ],
      "interventions": [
        {
          "name": "NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelwise Pharmaceutical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-11-20",
      "completion_date": "2029-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07136181"
    },
    {
      "nct_id": "NCT03207347",
      "title": "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Uveal Melanoma",
        "Renal Cell Carcinoma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 37,
      "start_date": "2018-08-13",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 3,
      "location_summary": "Gainesville, Florida • Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207347"
    },
    {
      "nct_id": "NCT04904120",
      "title": "Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Melanoma Stage IV",
        "Melanoma, Uveal",
        "Melanoma, Mucosal"
      ],
      "interventions": [
        {
          "name": "[203Pb]VMT01",
          "type": "DRUG"
        },
        {
          "name": "[68Ga]VMT02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perspective Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-03-05",
      "completion_date": "2022-09-20",
      "has_results": false,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04904120"
    },
    {
      "nct_id": "NCT06805825",
      "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Small-cell Lung Cancer",
        "Adenoid Cystic Carcinoma",
        "Uveal Melanoma",
        "Neuroendocrine Tumors",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "NN3201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelty Nobility, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2025-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805825"
    },
    {
      "nct_id": "NCT01251978",
      "title": "Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Melanoma"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 2 mg",
          "type": "DRUG"
        },
        {
          "name": "0.5 mg Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New England Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 10,
      "start_date": "2010-07",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 1,
      "location_summary": "Hamden, Connecticut",
      "locations": [
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251978"
    },
    {
      "nct_id": "NCT07636785",
      "title": "A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma (HCC)",
        "Metastatic Uveal Melanoma",
        "Renal Cell Carcinoma (RCC)",
        "Nonsmall Cell Lung Cancer",
        "Colorectal Cancer (CRC)"
      ],
      "interventions": [
        {
          "name": "VMD-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VM Discovery, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 111,
      "start_date": "2026-07-16",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07636785"
    },
    {
      "nct_id": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma or Advanced Solid Tumors",
        "Melanoma",
        "Uveal Melanoma",
        "P53 Mutation",
        "MDM2 Gene Mutation",
        "Cutaneous Melanoma",
        "Mucosal Melanoma",
        "Malignant Peripheral Nerve Sheath Tumors (MPNST)"
      ],
      "interventions": [
        {
          "name": "Phase 1b: APG-115+pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2018-08-29",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611868"
    },
    {
      "nct_id": "NCT00085189",
      "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ciliary Body and Choroid Melanoma, Medium/Large Size",
        "Ciliary Body and Choroid Melanoma, Small Size",
        "Extraocular Extension Melanoma",
        "Iris Melanoma",
        "Metastatic Intraocular Melanoma",
        "Mucosal Melanoma",
        "Recurrent Intraocular Melanoma",
        "Recurrent Melanoma",
        "Stage IIC Melanoma",
        "Stage IIIA Intraocular Melanoma",
        "Stage IIIA Melanoma",
        "Stage IIIB Intraocular Melanoma",
        "Stage IIIB Melanoma",
        "Stage IIIC Intraocular Melanoma",
        "Stage IIIC Melanoma",
        "Stage IV Intraocular Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant MAGE-3.1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "multi-epitope melanoma peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA 51 VG",
          "type": "DRUG"
        },
        {
          "name": "agatolimod sodium",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2004-05",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085189"
    },
    {
      "nct_id": "NCT02158520",
      "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Mucosal Melanoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-10-18",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-14T23:46:03.653Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02158520"
    }
  ]
}